Boston Scientific: Olympia trial meets endpoint

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Boston Scientific Corp. said six-month results of its phase 1 global Taxus Olympia registry in 529 patients demonstrated an overall Taxus Liberte-related cardiac event rate of 2.3%, including cardiac death (0.8%) and myocardial infarction (1.3%), as well as a stent thrombosis rate of 1.5%.

A lower Taxus Liberte-related cardiac event rate of 1.5% was reported in the subset of 261 diabetic patients.

The trial met its primary endpoint of stent-related events at 30 days post implant.

Boston Scientific is a Natick, Mass.-based medical-device company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.